Navigation Links
Thoratec Corporation Authorizes $100 Million Share Repurchase Program
Date:2/14/2011

PLEASANTON, Calif., Feb. 14, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of up to $100 million of the company's shares of common stock over the next year.

"This authorization reflects our confidence in the long-term strength of the company, as well as our focus on enhancing shareholder value. With nearly $470 million in cash and investments at the end of 2010, we believe we have the necessary financial resources to fund our market expansion and product development strategies, pursue business development opportunities, and return value to shareholders," said Gary F. Burbach, president and chief executive officer.

Repurchases will take place on the open market or in privately negotiated transactions from time to time based on market and other conditions.  The program is effective immediately, and it may be modified, suspended, terminated or extended by the company at any time without prior notice.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag is a registered trademark of Levitronix LLC.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address issues raised by FDA inspections adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations
2. Thoratec Schedules Fourth Quarter Conference Call, Webcast
3. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
4. Thoratec Announces Webcast of Investor Presentation at American Heart Association Meeting
5. Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations
6. Thoratec Schedules Third Quarter Conference Call, Webcast
7. Thoratec to Present at Upcoming Investor Conferences
8. Thoratec Announces Termination of Proposed Sale of ITC
9. Thoratec Schedules Second Quarter Conference Call, Webcast
10. Thoratec Announces Early Termination of HSR Waiting Period for the Sale of ITC to Danaher Corporation
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... ... to announce the addition of Zack Tisch as the firm’s new Consulting Services ... healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor selection ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... (RCM) solutions, announced recently the availability of a new professional fee E/M leveling ... for their service to the healthcare industry. E/M coding is complex which supports ...
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, ... replacement of auto glass for most makes and models, in Grand Prairie, TX, located in ... , They have been a family owned business for the past 40 years with 32 ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Wilderness Voices”: ... of world travel. “Wilderness Voices” is the creation of published author, Martha McKown, ... Martha McKown was inspired as a very young child when her older sisters studied ...
(Date:8/22/2017)... ... 2017 , ... “Covert Awakening”: Walid’s spiritual journey from Islamic ... Hale, a consultant for the Intelligence Community. For more than ten years, ... East region. Julianne has written hundreds of reports for the US government ...
Breaking Medicine News(10 mins):